Arbutus Biopharma (ABUS) Competitors

$4.34 +0.03 (+0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$4.34 0.00 (0.00%)

As of 04:04 PM Eastern

ABUS vs. BEAM, TNGX, ORKA, RCUS, and ERAS

Should you buy Arbutus Biopharma stock or one of its competitors? MarketBeat compares Arbutus Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arbutus Biopharma include Beam Therapeutics (BEAM), Tango Therapeutics (TNGX), Oruka Therapeutics (ORKA), Arcus Biosciences (RCUS), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry.

How does Arbutus Biopharma compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Beam Therapeutics has a net margin of -39.66% compared to Arbutus Biopharma's net margin of -237.88%. Beam Therapeutics' return on equity of -29.00% beat Arbutus Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Arbutus Biopharma	-237.88%	-42.39%	-32.48%

Beam Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Beam Therapeutics presently has a consensus target price of $46.83, indicating a potential upside of 58.56%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 15.34%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Beam Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Arbutus Biopharma has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$164.01M	18.53	-$79.99M	-$0.68	N/A
Arbutus Biopharma	$14.08M	60.62	-$33.50M	-$0.17	N/A

In the previous week, Beam Therapeutics had 7 more articles in the media than Arbutus Biopharma. MarketBeat recorded 12 mentions for Beam Therapeutics and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Beam Therapeutics' score of 0.72 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Arbutus Biopharma on 11 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, Tango Therapeutics had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for Tango Therapeutics and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Tango Therapeutics' score of 0.86 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	57.53	-$101.59M	-$0.87	N/A
Arbutus Biopharma	$14.08M	60.62	-$33.50M	-$0.17	N/A

Tango Therapeutics currently has a consensus target price of $28.00, indicating a potential upside of 12.54%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 15.34%. Given Arbutus Biopharma's higher probable upside, analysts plainly believe Arbutus Biopharma is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tango Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Tango Therapeutics has a net margin of -151.15% compared to Arbutus Biopharma's net margin of -237.88%. Arbutus Biopharma's return on equity of -42.39% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-50.30%	-36.25%
Arbutus Biopharma	-237.88%	-42.39%	-32.48%

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Arbutus Biopharma beats Tango Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Oruka Therapeutics?

Arbutus Biopharma (NASDAQ:ABUS) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Oruka Therapeutics had 6 more articles in the media than Arbutus Biopharma. MarketBeat recorded 11 mentions for Oruka Therapeutics and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Oruka Therapeutics' score of 1.16 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arbutus Biopharma has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	60.62	-$33.50M	-$0.17	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A

Arbutus Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

Arbutus Biopharma currently has a consensus target price of $5.00, indicating a potential upside of 15.34%. Oruka Therapeutics has a consensus target price of $120.80, indicating a potential upside of 89.34%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -237.88%. Oruka Therapeutics' return on equity of -25.48% beat Arbutus Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-237.88%	-42.39%	-32.48%
Oruka Therapeutics	N/A	-25.48%	-24.34%

Summary

Oruka Therapeutics beats Arbutus Biopharma on 9 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to Arcus Biosciences?

Arbutus Biopharma (NASDAQ:ABUS) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Arcus Biosciences had 11 more articles in the media than Arbutus Biopharma. MarketBeat recorded 16 mentions for Arcus Biosciences and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Arcus Biosciences' score of 0.27 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arbutus Biopharma has higher earnings, but lower revenue than Arcus Biosciences. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	60.62	-$33.50M	-$0.17	N/A
Arcus Biosciences	$236M	13.32	-$353M	-$3.18	N/A

Arbutus Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Arbutus Biopharma currently has a consensus target price of $5.00, indicating a potential upside of 15.34%. Arcus Biosciences has a consensus target price of $33.33, indicating a potential upside of 33.41%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Arcus Biosciences has a net margin of -156.36% compared to Arbutus Biopharma's net margin of -237.88%. Arbutus Biopharma's return on equity of -42.39% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-237.88%	-42.39%	-32.48%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Summary

Arcus Biosciences beats Arbutus Biopharma on 10 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Erasca?

Erasca (NASDAQ:ERAS) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Erasca presently has a consensus target price of $18.75, suggesting a potential upside of 80.72%. Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential upside of 15.34%. Given Erasca's stronger consensus rating and higher probable upside, research analysts clearly believe Erasca is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

67.8% of Erasca shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Erasca has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Erasca has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -237.88%. Erasca's return on equity of -35.31% beat Arbutus Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Arbutus Biopharma	-237.88%	-42.39%	-32.48%

Arbutus Biopharma has higher revenue and earnings than Erasca. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Arbutus Biopharma	$14.08M	60.62	-$33.50M	-$0.17	N/A

In the previous week, Erasca had 18 more articles in the media than Arbutus Biopharma. MarketBeat recorded 23 mentions for Erasca and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.19 beat Erasca's score of 0.10 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Erasca beats Arbutus Biopharma on 10 of the 15 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABUS vs. The Competition

Export

Metric	Arbutus Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$853.74M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-25.50	18.81	20.87	25.61
Price / Sales	60.62	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	10.84	6.75	9.86	6.71
Net Income	-$33.50M	$24.11M	$3.55B	$333.77M
7 Day Performance	-0.34%	0.11%	-0.26%	0.40%
1 Month Performance	-0.34%	0.87%	1.39%	4.03%
1 Year Performance	37.18%	78.18%	41.07%	36.33%

Arbutus Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABUS Arbutus Biopharma	1.6856 of 5 stars	$4.34 +0.6%	$5.00 +15.3%	+35.1%	$853.74M	$14.08M	N/A	90	Earnings Report
BEAM Beam Therapeutics	3.991 of 5 stars	$31.75 -1.8%	$47.17 +48.6%	+76.5%	$3.33B	$139.74M	N/A	510	News Coverage Earnings Report Analyst Forecast
TNGX Tango Therapeutics	1.9872 of 5 stars	$23.48 +2.0%	$22.44 -4.4%	+1,722.1%	$3.32B	$62.38M	N/A	90	Earnings Report Analyst Upgrade Gap Down
ORKA Oruka Therapeutics	3.6623 of 5 stars	$65.68 +1.7%	$120.80 +83.9%	+556.8%	$3.24B	N/A	N/A	N/A	Positive News Earnings Report Analyst Forecast
RCUS Arcus Biosciences	3.346 of 5 stars	$24.87 -2.0%	$33.33 +34.1%	+188.9%	$3.19B	$247M	N/A	500	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABUS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Competitors

ABUS vs. BEAM, TNGX, ORKA, RCUS, and ERAS

How does Arbutus Biopharma compare to Beam Therapeutics?

Summary

How does Arbutus Biopharma compare to Tango Therapeutics?

Summary

How does Arbutus Biopharma compare to Oruka Therapeutics?

Summary

How does Arbutus Biopharma compare to Arcus Biosciences?

Summary

How does Arbutus Biopharma compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Competitors

ABUS vs. BEAM, TNGX, ORKA, RCUS, and ERAS

How does Arbutus Biopharma compare to Beam Therapeutics?

Do insiders & institutionals believe in BEAM or ABUS?

Is BEAM or ABUS more profitable?

Which has more volatility & risk, BEAM or ABUS?

Do analysts rate BEAM or ABUS?

Which has preferable valuation and earnings, BEAM or ABUS?

Does the media prefer BEAM or ABUS?

Summary

How does Arbutus Biopharma compare to Tango Therapeutics?

Does the media favor TNGX or ABUS?

Which has higher earnings & valuation, TNGX or ABUS?

Do analysts prefer TNGX or ABUS?

Which has more volatility & risk, TNGX or ABUS?

Is TNGX or ABUS more profitable?

Do institutionals & insiders believe in TNGX or ABUS?

Summary

How does Arbutus Biopharma compare to Oruka Therapeutics?

Does the media refer more to ABUS or ORKA?

Do insiders and institutionals have more ownership in ABUS or ORKA?

Which has stronger earnings and valuation, ABUS or ORKA?

Which has more risk & volatility, ABUS or ORKA?

Do analysts prefer ABUS or ORKA?

Is ABUS or ORKA more profitable?

Summary

How does Arbutus Biopharma compare to Arcus Biosciences?

Does the media refer more to ABUS or RCUS?

Do institutionals and insiders have more ownership in ABUS or RCUS?

Which has preferable earnings & valuation, ABUS or RCUS?

Which has more volatility and risk, ABUS or RCUS?

Do analysts prefer ABUS or RCUS?

Is ABUS or RCUS more profitable?

Summary

How does Arbutus Biopharma compare to Erasca?

Do analysts recommend ERAS or ABUS?

Do insiders & institutionals have more ownership in ERAS or ABUS?

Which has more volatility and risk, ERAS or ABUS?

Is ERAS or ABUS more profitable?

Which has higher valuation & earnings, ERAS or ABUS?

Does the media favor ERAS or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools